ER ER ER ER - Endocrine Reviews

173. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G,
Alligood KJ, Spector NL 2002 Anti-tumor activity of GW572016: a dual
tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream
Erk1/2 and AKT pathways. Oncogene 21:6255-63
174. Blackwell K, Kaplan EH, Franco SX, Marcom PK, Maleski JE, Sorensen
MJ, Berger MS 2004 A phase II, open label, multicenter study of GW572016 in
patients with trastuzumab-refractory metastatic breast cancer. Proceeding of the
American Society of Clinical Oncology. 22:3006
175. Burris HA, 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B,
Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch
KM, Stead A, Mangum S, Spector NL 2005 Phase I safety, pharmacokinetics,
and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of
epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients
with metastatic carcinomas. J Clin Oncol 23:5305-13
176. Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N,
Mann G, Tao Y, Ellis MJ 2006 The combination of letrozole and trastuzumab as
first or second-line biological therapy produces durable responses in a subset of
HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat
102(1):43-9
177. Mackey JR, Kaufman B, Clemens M, Bapsy PP, Vaid A, Wardley A,
Tjulandin S, Jahn M, Lehle M, Jones A Trastuzumab prolongs progression-free
survival in hormone-dependent and HER2-positive metastatic breast cancer. San
68